Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Enlivex ( (ENLV) ).
On May 18, 2026, Enlivex announced it had dosed the first patient at a U.S. clinical site in its global Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis, following FDA IND clearance in March and Danish regulatory approval in April. The randomized, double-blind, placebo-controlled study spans sites in the United States, Denmark and Poland, assessing pain, physical function, quality-of-life and mobility outcomes, and the company views this milestone as a key step toward late-stage development in a large, underserved osteoarthritis market.
Management highlighted that the United States is the largest clinical network for the trial and noted earlier Phase 1/2a data showed robust and durable effects in the target patient group, underlining Allocetra’s potential to address a major unmet need in a condition affecting tens of millions of aging patients. The advancement of this trial strengthens Enlivex’s positioning at the intersection of longevity therapeutics and its prediction markets treasury strategy, with meaningful implications for investors tracking both its clinical progress and its unconventional digital asset–backed capital deployment model.
The most recent analyst rating on (ENLV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is primarily constrained by weak financial performance—minimal revenue, ongoing operating losses, and continued cash burn—despite low leverage. Technicals also weigh on the rating as the stock trades below major moving averages with negative MACD. Valuation appears optically cheap due to the very low P/E, but that support is limited given questions about the sustainability of the reported earnings.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd. is a “quality longevity” company developing Allocetra, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. Alongside its therapeutics pipeline, the company runs a prediction markets–based digital asset treasury strategy built around the Rain protocol on Arbitrum, combining drug development with exposure to decentralized prediction markets.
Average Trading Volume: 552,825
Technical Sentiment Signal: Sell
Current Market Cap: $171.1M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.